MarginsXMarginsX
Home › Markets › Health Care › NVCR

NovoCure Limited (NVCR)

NVCR trades on Nasdaq in Health Care, Medical/Dental Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$11.30
-4.48% on the day
Market cap
$1.3B
Small cap
Revenue · 2025
$655.4M
+8.3% on 2024
Net income · 2025
-$136.2M
-20.8% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1645113/000164511326000017/0001645113-26-000017-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerNVCR on Nasdaq
SectorHealth Care
IndustryMedical/Dental Instruments
CountryJersey
IPO year2015
SEC CIK0001645113
SEC industry codeSurgical & Medical Instruments & Apparatus

Financials · 2025

LineValue
Revenue$655.4M
Net income-$136.2M
Operating income-$153.8M
Net margin-20.8%
Operating margin-23.5%
Revenue growth+8.3%
Cash$93.5M
Total assets$804.3M
P/E (computed)Net income was not positive
P/S (computed)2.0×

Warning signs

Cash runway
1607.8 months
$96.7M cash at September 30, 2026
Share count, 1 year
+4.4%
2025-10-24 to 2026-10-23 · +9.4% over 3 years
Going-concern doubt
No
10-Q filed October 29, 2026
Insider net buying, 12 months
-$2.9M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-10-29
Cash and burn$96.7M cash; operating cash flow -$181K a quarter.Report 2026-09-30
Shares outstanding116,915,959 (2026-10-23); 111,981,981 a year earlier; 106,861,113 three years earlier.Cover page 2026-10-23
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKost Forer Gabbay & Kasierer, Tel Aviv, IsraelPCAOB Form AP 2026-03-24
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $2.9M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$193.4M-$10.4M$22.7M$96.7M$25.0M$725.4M10-Q 2026-10-29
Q2 2026
2026-06-30
$183.6M-$15.7M$8.1M$93.7MNo debt tags$699.2M10-Q 2026-07-23
Q1 2026
2026-03-31
$174.1M-$71.1M-$13.5M$87.5MNo debt tags$674.4M10-Q 2026-04-30
Q4 2025
2025-12-31
$174.3M-$24.5M-$18.0M$93.5M$195.0M$655.4M10-Q 2026-10-29
Q3 2025
2025-09-30
$167.2M-$37.3M$20.6M$342.1M$560.6M$642.3M10-Q 2026-10-29
Q2 2025
2025-06-30
$158.8M-$40.1M-$15.9M$149.6M$559.8M$630.2M10-Q 2026-07-23
Q1 2025
2025-03-31
$155.0M-$34.3M-$35.7M$127.3M$559.0M$621.7M10-Q 2026-04-30
Q4 2024
2024-12-31
$161.3M-$65.9M-$3.5M$163.8M$97.3M$605.2M10-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest annual report10-K2026-02-26
Latest quarterly / interim10-Q2026-10-29
Latest current report8-K2026-11-09
Latest proxyDEFA14A2026-05-21

Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-10.9%
1 month-17.3%
3 months-31.9%
Year to date-8.5%
1 year+4.0%
From 52-week high-40.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Medical/Dental Instruments

TickerCompanyPriceDayMarket cap
TNDMTandem Diabetes Care Inc.$18.48-7.92%$1.3B
PRCTPROCEPT BioRobotics Corporation$23.54-1.09%$1.4B
DRTSAlpha Tau Medical Ltd.$11.97-10.54%$1.1B
IARTIntegra LifeSciences Holdings Corporation$13.98-2.92%$1.1B
IRMDiRadimed Corporation$84.84-0.60%$1.1B
SGPSpyGlass Pharma Inc.$32.24-1.95%$1.1B
SIBNSI-BONE Inc.$23.41-0.13%$1.1B
ATECAlphatec Holdings Inc.$6.78-4.10%$1.1B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier